We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Getting stronger and stronger over the pond so hopefully see a move back over 30p here shortly
We are now !!! When this goes it won't stop.
GLA
We should be surging upwards surely ?
Holding and hoping one day these will be back in the £££
The news is OK but I think sentiment here got shot to pieces after the DMD debacle and it will take something really solid to turn the sp in the upwards direction. Bottom drawer still. (Although I have been sorely tempted to take my losses and come back in a year or so!)
What do people make of today news?
Summit Therapeutics plc
(‘Summit’ or the ‘Company’)
Summit Therapeutics to Participate in Upcoming Investor Conferences
Oxford, UK, and Cambridge, MA, US, 4 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that management will participate in several upcoming investor conferences taking place in New York City.
9 September 2019 – Janney Healthcare Conference
10 September 2019 – H.C. Wainwright 21st Annual Global Investment Conference, presentation at 12:05pm EDT
23-24 September 2019 – Oppenheimer Fall Summit
A live webcast of the H.C. Wainwright presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation. There will be no podium presentations at the Janney and Oppenheimer conferences.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
It maybe just me but I have not been able to find the presentation from the
Canaccord Genuity Growth Conference & so phoned Summit this afternoon it is a matter of clicking on the title per link below:
https://www.summitplc.com/app/uploads/2019/08/201908_Corporate-Presentation-Aug-Canaccord-final.pdf
Per waterloo01 from the other board this morning:
https://www.dailymail.co.uk/news/article-7409059/Forget-climate-change-antibiotics-crisis-kill-says-NHS-chief.html
NHS chief says that superbugs could kill us before climate change does
Dame Sally Davies warns 10million people could die every year from superbugs
England's chief medical officer says we are 'underinvesting in sorting it out'
OMG, There is still somebody out there that has the faith !!
GL Bermudashorts & all LTH'S
Courtesy of Waterloo, Summit and ridinilazole get a mention in following article in FT today.
https://www.ft.com/content/5b26b9ec-8d2d-11e9-b8cb-26a9caa9d67b
Per waterloo01 from the other board:
'This is interesting, FDA just approved new antibiotic under limited population pathway. Only 107 in trial. Must really fast track approval. Hopefully for the Gonorrhoea trial?
This approval also marks the second time a drug is being approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, a pathway, advanced by Congress, to spur development of drugs targeting infections that lack effective therapies.'
http://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs
First feedback from waterloo01 from todays presentation:
RDZ building the use case, saving $5000/$6000 per patient (because of reduced recurrence from 30% vanco and 14% RDZ).
Pushing both it's health and economic benefits suggesting that even if no changes in the antibiotic landscape.
My Edit: The adding in of the cost benefits to using the Summit drug RDZ was an interesting extra to the presentation & must show added value to using RDZ if successful.It does I agree add a bit more meat on the bone.
Is anyone listening this Thursday?
Canaccord Genuity Growth Conference:
https://www.summitplc.com/investors/events-presentations/
Interesting interactive tool in link below highlights just how few new ABs are in development - you can track the trend over the last 5 years and the progress of individual drugs, including Ridinilazole. Just hit the play button above 2014.
https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2019/five-year-analysis-shows-continued-deficiencies-in-antibiotic-development
Nasdaq has seen a good run and the Nasdaq drives lse
Summit Therapeutics flags potential of new antibiotic to treat drug-resistant gonorrhoea
https://www.proactiveinvestors.co.uk/companies/news/224070/summit-therapeutics-flags-potential-of-new-antibiotic-to-treat-drug-resistant-gonorrhoea-224070.html
BioCentury - ?@Summitplc R&D Head outlines to do list for U.K. antibiotics initiative to succeed
https://m.biocentury.com/bc-extra/politics-policy/2019-07-11/former-crick-coo-outlines-do-list-uk-antibiotics-initiative-
Edit: Makes for a good read we are really lucky to have Roblin on board.
PS: I had an interesting chat with Roblin at the recent AGM.
FT Video worth a watch (the message is getting out there).
The drugs don't work: a global antibiotics crisis:
https://www.ft.com/video/9c81b3ee-f470-41f0-913f-47dc9692801a?playlist-name=latest&playlist-offset=1
Interesting to see if this encourages other countries to adopt the same approach. In isolation the UK isn't going to incentivise a company to develop an antimicrobial (the UK is a small proportion of the global market) but interesting to see if taking the lead gets others to follow? Really just need the US to take a similar approach now with DISARM - knowing the US though they like to lead rather than follow...
As a pilot, in isolation, it's unlikely to change much (the payment from the NHS/UK won't touch the sides of the development costs) but someone has to do something, so lets hope we see the approach adopted elsewhere.
Interesting development today:
Development of new antibiotics encouraged with new pharmaceutical payment system:
The NHS will test the world's first ‘subscription’ style payment model to incentivise pharmaceutical companies to develop new drugs for resistant infections.
https://www.gov.uk/government/news/development-of-new-antibiotics-encouraged-with-new-pharmaceutical-payment-system
Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
Proof of Concept Now Established in Animal Models Across Key Enterobacteriaceae Indications
Pathogen-Targeted Approach Seeks to Preserve Patients’ Microbiomes
Oxford, UK, and Cambridge, MA, US, 9 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that it has demonstrated the potential of its DDS-04 series of new class antibiotics as an Enterobacteriaceae-targeted treatment through in vivo proof of concept data in sepsis and pneumonia animal models. These data build on the previously published proof of concept preclinical study for DDS-04 in urinary tract infections. Enterobacteriaceae are a family of Gram-negative bacteria that cause severe and often deadly infections.
more here.. https://www.globenewswire.com/news-release/2019/07/09/1880014/0/en/Summit-s-DDS-04-Enterobacteriaceae-Programme-Demonstrates-In-Vivo-Efficacy-in-Sepsis-and-Pneumonia.html
Can’t see an rns ?
Dead investment nothing happening